Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an acquired metabolic stress-induced liver disease associated closely with genetic susceptibility and insulin resistance (IR), the spectrum of the disease includes non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and related liver cirrhosis, and hepatocellular carcinoma (HCC).1,2 This article is protected by copyright. All rights reserved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Data from clinical trials in the United States have shown that oral vitamin E (α-tocopherol) at a daily dose of 800 IU for 2 years improves serum transaminases and liver histology in non-diabetic adults with biopsy-proven NASH.(63) In China, vitamin E is not listed as a medical treatment option for chronic liver disea…”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875 · cited 1×
“However, ultrasound has low sensitivity for diagnosing mild steatosis and lacks specificity, because “bright liver” could be observed in patients with diffuse liver fibrosis and early cirrhosis as well.(39) Using vibration controlled transient elastography (VCTE) to obtain controlled attenuation parameter (CAP) is a n…”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · cited 1×
“patitis (NASH) and related liver cirrhosis, and hepatocellular carcinoma (HCC).(1,2) NAFLD not only causes liver disease-related”
BackgroundKarlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275 · cited 1×
“CT and MRI are often used to confirm ultrasonic finding of fatty liver with islands of normal liver, focal fatty changes and space-occupying lesion.(42) Magnetic resonance spectroscopy (MRS) and MRI-based proton density fat fraction (MRI-PDFF) were more accurate than CAP for detecting hepatic steatosis in patients wit…”
BackgroundSelf-citationCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 12×
“When needed, these patients should also have a standard OGTT of 75 g glucose to screen for impaired glucose tolerance and T2DM.8,48 Except for polymorphism PNPLA3 I148Massociated NAFLD, IR is the most common feature in both NAFLD and NASH patients.”
BackgroundInfluentialAthyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Zhang, H.-J., He, J., Pan, L.-L., Ma, Z.-M., Han, C.-K., Chen, C.-S., Chen, Z., Han, H.-W., Chen, S., Sun, Q., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3202 · Cited by 276
A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis
Wah Kheong, C., Nik Mustapha, N. R., & Mahadeva, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.016 · Cited by 264
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Ajmera, V. H., Terrault, N. A., & Harrison, S. A. (2017) · Hepatology · doi:10.1002/hep.29055 · Cited by 137 · cited 1×
“Additionally, long-term alcohol consumption, even at a low dose, can increase HCC risk in NAFLD patients with liver fibrosis.(69) Consumption of coffee and tea drinking may help recovery for NAFLD patients.”
BackgroundBril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97 · cited 1×
“While using statins, patients may develop asymptomatic and isolated elevation of serum ALT level, which usually returns to normal range without dose reduction or drug withdrawn.(56,57) Although metformin does not have any effect on NASH, it can be used to improve IR, lower blood glucose in T2DM, and assist weight loss.”
Cited by
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
Yang, Y., Gu, M., Wang, W., Li, S., Lu, J., Sun, Q., Hu, M., & Zhong, L. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01316-0 · Cited by 10
Metadata
- Authors
- Fan, J. G., Wei, L., Zhuang, H., & On behalf of the National Workshop on Fatty Liver and Alcoholic Liver Disease, C. S. O. H.
- Venue
- Journal of Digestive Diseases
- Publisher
- Wiley
- Published
- 2018-12-11
- Volume
- 20
- Issue
- 4
- Pages
- 163-173
- ISSN
- 1751-2972 (ISSN-L)
- 1751-2980
- OpenAlex
- W2900934742
- Cited by
- 198
- References
- 20
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.